These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 8724043)

  • 1. Randomized cross-over comparison of liposomal daunorubicin versus observation for early Kaposi's sarcoma.
    Uthayakumar S; Bower M; Money-Kyrle J; Muyshondt C; Youle M; Hannon F; Phillips R; Gazzard BG; Boag F
    AIDS; 1996 May; 10(5):515-9. PubMed ID: 8724043
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liposomal daunorubicin is not recommended in patients with less than advanced HIV-related Kaposi's sarcoma.
    White RM
    AIDS; 1997 Sep; 11(11):1412-3. PubMed ID: 9302461
    [No Abstract]   [Full Text] [Related]  

  • 3. Phase II study of liposomal encapsulated daunorubicin in the treatment of AIDS-associated mucocutaneous Kaposi's sarcoma.
    Girard PM; Bouchaud O; Goetschel A; Mukwaya G; Eestermans G; Ross M; Rozenbaum W; Saimot AG
    AIDS; 1996 Jun; 10(7):753-7. PubMed ID: 8805866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma.
    Gill PS; Wernz J; Scadden DT; Cohen P; Mukwaya GM; von Roenn JH; Jacobs M; Kempin S; Silverberg I; Gonzales G; Rarick MU; Myers AM; Shepherd F; Sawka C; Pike MC; Ross ME
    J Clin Oncol; 1996 Aug; 14(8):2353-64. PubMed ID: 8708728
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II trial of liposomal daunorubicin in the treatment of AIDS-related pulmonary Kaposi's sarcoma.
    Tulpule A; Yung RC; Wernz J; Espina BM; Myers A; Scadden DT; Cabriales S; Ilaw M; Boswell W; Gill PS
    J Clin Oncol; 1998 Oct; 16(10):3369-74. PubMed ID: 9779714
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness analysis comparing liposomal anthracyclines in the treatment of AIDS-related Kaposi's sarcoma.
    Bennett CL; Golub RM; Stinson TJ; Aboulafia DM; von Roenn J; Bogner J; Goebel FD; Stewart S
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Aug; 18(5):460-5. PubMed ID: 9715842
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kaposi's sarcoma: DaunoXome approved.
    AIDS Treat News; 1996 May; (no 246):3-4. PubMed ID: 11363485
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness analysis of pegylated-liposomal doxorubicin and liposomal daunorubicin treatments in patients with Kaposi's sarcoma.
    Hjortsberg C; Persson U; Lidbrink E; Bennett C
    Acta Oncol; 1999; 38(8):1063-7. PubMed ID: 10665764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The pharmacokinetics of liposomal encapsulated daunorubicin are not modified by HAART in patients with HIV-associated Kaposi's sarcoma.
    Fumagalli L; Zucchetti M; Parisi I; Viganò MG; Zecca B; Careddu A; D'Incalci M; Lazzarin A
    Cancer Chemother Pharmacol; 2000; 45(6):495-501. PubMed ID: 10854138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and tolerance of liposomal daunorubicin in Kaposi sarcoma associated with human immunodeficiency virus infection.
    Fournier S; Dupont B; Pialoux G; Eliaszewicz M; Gonzalez-Canali G; Feuillie V
    Arch Dermatol; 1997 Jul; 133(7):918-9. PubMed ID: 9236538
    [No Abstract]   [Full Text] [Related]  

  • 11. Liposomal daunorubicin: new preparation. Kaposi's sarcoma: occasional remission.
    Prescrire Int; 1998 Apr; 7(34):41-2. PubMed ID: 10183380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacology of liposomal daunorubicin and its use in Kaposi's sarcoma.
    Chew T; Jacobs M
    Oncology (Williston Park); 1996 Jun; 10(6 Suppl):28-33; discussion 37-8. PubMed ID: 16871707
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liposomal daunorubicin in advanced Kaposi's sarcoma: a phase II study.
    Money-Kyrle JF; Bates F; Ready J; Gazzard BG; Phillips RH; Boag FC
    Clin Oncol (R Coll Radiol); 1993; 5(6):367-71. PubMed ID: 8305357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paclitaxel for treating KS.
    Proj Inf Perspect; 1997 Nov; (23):15. PubMed ID: 11365372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complete response of an HIV negative gastric Kaposi's sarcoma (KS) patient with peritoneal carcinomatosis by liposomal daunorubicin treatment.
    Fléchon A; Lombard-Bohas C; Boulez J; Blay JY; Scoazec JY
    Ann Oncol; 2001 Feb; 12(2):275-6. PubMed ID: 11300338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liposomal daunorubicin treatment of HIV-associated Kaposi's sarcoma.
    Presant CA; Scolaro M; Kennedy P; Blayney DW; Flanagan B; Lisak J; Presant J
    Lancet; 1993 May; 341(8855):1242-3. PubMed ID: 8098393
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase IV study of liposomal daunorubicin (DaunoXome) in AIDS-related Kaposi sarcoma.
    Rosenthal E; Poizot-Martin I; Saint-Marc T; Spano JP; Cacoub P;
    Am J Clin Oncol; 2002 Feb; 25(1):57-9. PubMed ID: 11823698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extravasation of liposomal daunorubicin in patients with AIDS-associated Kaposi's sarcoma: a report of four cases.
    Cabriales S; Bresnahan J; Testa D; Espina BM; Scadden DT; Ross M; Gill PS
    Oncol Nurs Forum; 1998; 25(1):67-70. PubMed ID: 9460774
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin.
    Gill PS; Espina BM; Muggia F; Cabriales S; Tulpule A; Esplin JA; Liebman HA; Forssen E; Ross ME; Levine AM
    J Clin Oncol; 1995 Apr; 13(4):996-1003. PubMed ID: 7707129
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liposomal daunorubicin marketed for HIV-related Kaposi's sarcoma.
    Am J Health Syst Pharm; 1996 Jul; 53(13):1500, 1505. PubMed ID: 8809269
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.